ipilimumab,nivolumab
bms
['sclc', 'lcsm,(-blcsm)', 'lung', 'alta', 'nivo', 'ipi/', 'nsclc', 'award']
dr. mehmet altan, recipient of 2017 cda award from lungevity, presents a poster about identifying a potential subset of patients who benefit from continuing with ipi/nivo after progression. more studies needed. #asco22 #lcsm #nsclc 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.